Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 13, 2019 08:30 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics to Participate in 33rd Annual National MPS Society Family Conference

NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
December 04, 2019 08:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)

NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
November 27, 2019 11:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces Dosing of Phase I PK/PD Study of Intranasal Racemic Ketamine (SLS-002)

NEW YORK, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
November 20, 2019 09:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces Initial Dosing of Phase I DDI Study of Intranasal Racemic Ketamine (SLS-002)

NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
November 18, 2019 08:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Receives FDA Fast Track Designation for Intranasal Racemic Ketamine (SLS-002)

NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
November 08, 2019 07:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Reports Q3 2019 Pipeline Update

NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today released its third quarter pipeline update. “Seelos continued...
November 01, 2019 10:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics to Participate in Upcoming Investor Conferences in December

NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Evercore ISI 2nd...
October 21, 2019 09:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces Amendment of SLS-002 Agreement

Seelos Plans to Study SLS-002 Initially in Suicidality in Major Depressive Disorder NEW YORK, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage...
October 18, 2019 09:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics to Participate in Upcoming Investor Conference in November

NEW YORK, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Jefferies 2019...
October 15, 2019 09:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces the Addition of Scott Applebaum as Lead Strategic Regulatory Consultant

NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today announced the addition of Scott Applebaum to its team as lead...